Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy

Overview

Journal Transl Androl Urol

Date 2016 Jun 15

PMID 27296873

Citations 1

Authors

Andrew Leone

Gregory Diorio

Kamran Zargar-Shoshtari

Philippe E Spiess

Affiliations

Soon will be listed here.

Citing Articles

Erratum to comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy.

Transl Androl Urol. 2016; 5(4):632.

PMID: 27652239 PMC: 5002009. DOI: 10.21037/tau.2016.07.08.

References

Wood C, Margulis V . Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer. 2009; 115(10 Suppl):2355-60. DOI: 10.1002/cncr.24240. View

James A, Lee F, Izard J, Harris W, Cheng H, Zhao S . Role of maximal endoscopic resection before cystectomy for invasive urothelial bladder cancer. Clin Genitourin Cancer. 2014; 12(4):287-91. DOI: 10.1016/j.clgc.2014.01.005. View

Tsao C, Small A, Moshier E, Gartrell B, Wisnivesky J, Sonpavde G . Trends in the use of cytoreductive nephrectomy in the United States. Clin Genitourin Cancer. 2012; 10(3):159-63. PMC: 4744481. DOI: 10.1016/j.clgc.2012.03.008. View

Culp S, Tannir N, Abel E, Margulis V, Tamboli P, Matin S . Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?. Cancer. 2010; 116(14):3378-88. DOI: 10.1002/cncr.25046. View

Kutikov A, Uzzo R, Caraway A, Reese C, Egleston B, Chen D . Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int. 2009; 106(2):218-23. PMC: 2906619. DOI: 10.1111/j.1464-410X.2009.09079.x. View

Chapin B, Delacroix Jr S, Culp S, Nogueras Gonzalez G, Tannir N, Jonasch E . Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol. 2011; 60(5):964-71. PMC: 4378825. DOI: 10.1016/j.eururo.2011.05.032. View

Abel E, Culp S, Tannir N, Matin S, Tamboli P, Jonasch E . Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol. 2010; 59(1):10-5. PMC: 4378833. DOI: 10.1016/j.eururo.2010.09.034. View

Tomaszewski J, Smaldone M, Uzzo R, Kutikov A . Is radical nephrectomy a legitimate therapeutic option in patients with renal masses amenable to nephron-sparing surgery?. BJU Int. 2014; 115(3):357-63. DOI: 10.1111/bju.12696. View

OMalley R, Brewer K, Hayn M, Kim H, Underwood 3rd W, Pili R . Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible?. Urology. 2011; 78(3):595-600. DOI: 10.1016/j.urology.2011.03.009. View

10.

Linehan W, Spellman P, Ricketts C, Creighton C, Fei S, Davis C . Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2015; 374(2):135-45. PMC: 4775252. DOI: 10.1056/NEJMoa1505917. View

11.

Gershman B, Moreira D, Boorjian S, Lohse C, Cheville J, Costello B . Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy. Eur Urol. 2015; 69(1):84-91. DOI: 10.1016/j.eururo.2015.05.022. View

12.

Culp S . Cytoreductive nephrectomy and its role in the present-day period of targeted therapy. Ther Adv Urol. 2015; 7(5):275-85. PMC: 4549699. DOI: 10.1177/1756287215585501. View